Diabetes on the Net is intended for healthcare professionals
The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim andLilly Diabetes Alliance products will be discussed in this webcast.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 3281627 (freephone)
Defined as new patients prescribed JARDIANCE, patients switched to JARDIANCE from another type 2 diabetes treatment or JARDIANCE added to another type 2 diabetes treatment